The split verdict in the first trial of a pair of long-term Vioxx users' cases against Merck & Co. supports its strategy of battling each claim rather than settling the more than 10,000 cases, litigators say. "Merck's clearly going to keep taking these cases into the courtroom," said Peter A. Bicks, a products liability litigator for Orrick, Herrington & Sutcliffe who is not involved in Vioxx litigation. Bicks said the length of jury deliberations suggested that "the case was close and winnable for Merck."
Font Size: 
Litigators Watching Vioxx Trials Predict Merck Will Stay the Course
The National Law Journal
April 20, 2006
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.
